ABSTRACT
Background: Diabetes has been related to a higher risk of breast cancer (BC) in women. However, it remains unknown whether the incidence of BC is increased in women with prediabetes. A systematic review and meta-analysis was therefore performed to evaluate the relationship between prediabetes and risk of BC. Methods: Observational studies with longitudinal follow-up relevant to the objective were found via searching Medline, Embase, Cochrane Library, and Web of Science. A fixed- or random-effects model was used to pool the results depending on heterogeneity. Results: Eight prospective cohort studies and two nest case-control studies were included. A total of 1069079 community women were involved, and 72136 (6.7%) of them had prediabetes at baseline. During a mean duration follow-up of 9.6 years, 9960 (0.93%) patients were diagnosed as BC. Pooled results with a fixed-effects model showed that women with prediabetes were not associated with a higher incidence of BC as compared to those with normoglycemia (risk ratio: 0.99, 95% confidence interval: 0.93 to 1.05, p = 0.72) with mild heterogeneity (p for Cochrane Q test = 0.42, I2 = 3%). Subgroup analyses showed that study characteristics such as study design, menopausal status of the women, follow-up duration, diagnostic criteria for prediabetes, methods for validation of BC cases, and study quality scores did not significantly affect the results (p for subgroup analyses all > 0.05). Conclusion: Women with prediabetes may not be associated with an increased risk of BC as compared to women with normoglycemia.
ABSTRACT
BACKGROUND: The increased prevalence of gestational diabetes mellitus (GDM) has caused a huge societal economic and healthy burden at both the population and individual levels. We aimed to assess the comparative efficiency and safety of the use of glyburide, metformin, and insulin in GDM from a protocol for systematic review and meta-analysis. METHODS: Two individual researchers conducted the platform searches on the PubMed, Cochrane Library, and Embase databases from inception to February 2022. Literature retrieving was carried out through a combined searching of subject terms ("MeSH" on PubMed and "Emtree" on "Embase") and free terms on the platforms of PubMed and Embase, and through keywords searching on platform of Cochrane Library. Systematic review and meta-analysis of the data will be performed in STATA13.0 software according to the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Two authors independently performed the literature searching, data extraction, and quality evaluation. Risk of bias was assessed using the Cochrane Risk of Bias Tool for randomized controlled trials. RESULTS: The results will be submitted to a peer-reviewed journal. CONCLUSION: This meta-analysis will provide a comprehensive analysis and synthesis that can be used as an evidence map to inform practitioners and policy makers about the effectiveness of glyburide, metformin, and insulin for patients with GDM.
Subject(s)
Diabetes, Gestational , Metformin , Diabetes, Gestational/drug therapy , Female , Glyburide/adverse effects , Humans , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Meta-Analysis as Topic , Metformin/adverse effects , Pregnancy , Systematic Reviews as TopicABSTRACT
OBJECTIVES: This study aims to investigate the clinical value of uric acid in predicting adverse pregnancy outcomes (APOs) of women with hypertensive disorders of pregnancy. MATERIAL AND METHODS: A total of 180 pregnant women with HDP from September 2015 to January 2017 were selected for this study. These subjects were classified into two groups, according to serum uric acid level: high UA group (n = 137) and normal UA group (n = 43). In addition, 180 healthy pregnant women were selected and assigned as the control group (n = 180). The monitored biochemical indices and APOs in these three groups were analyzed. Furthermore, non-conditional logistic regression analysis was performed to determine influencing factors of APOs in women with HDP and hyperuricemia. RESULTS: The non-conditional multi-factor logistic regression analysis revealed that HUA (SUA > 357 umol/L) is the risk factor of APOs in women with HDP (OR = 1.258, P < 0.05). CONCLUSIONS: Women with HDP and HUA are often accompanied with a variety of abnormal biochemical indicators, and is correlated with the severity of the disease and APOs.
